# Phase 9 — Independent External Assurance Gate

**Decision:** `NOT COMPLETE`  
**Entry condition:** Phase 8 must be accepted before Phase 9 can be completed.

## Objective

Define the minimum reviewable evidence contract for independent external assurance of DTMO without weakening separation of duties, privacy, provenance, auditability, RBAC, secrets handling or human external-share approval.

This gate defines what evidence will be required; it does not claim that external assurance has already occurred.

## Current lifecycle context

- Phases 1–7: `PASS`;
- RC13 functional product: `PASS / OWNER_ACCEPTED`;
- Phase 8 real staging: `READY / PENDING_EXTERNAL_DEPLOYMENT_IDENTITY`;
- Phase 9 independent assurance: `NOT COMPLETE`;
- Phase 10 production go/no-go: `NOT STARTED`.

Phase 9 assurance should be performed against an approved, immutable and representative target identity. Wherever practical, that target should derive from the accepted Phase 8 production-equivalent staging/production-candidate baseline.

## Required assurance classes

### 1. Independent penetration test

Evidence must record:

- independent assessor/organization;
- scope and rules of engagement;
- immutable target release/environment identity;
- execution dates;
- methodology/coverage;
- findings and severity method;
- remediation/risk disposition;
- retest/closure evidence where applicable.

### 2. Representative load and stress validation

Record:

- workload model and provenance;
- immutable target identity;
- concurrency/volume assumptions;
- accepted thresholds/SLOs;
- privacy-safe measurements;
- bottlenecks/failure modes;
- remediation/disposition.

Repository performance gates remain useful engineering baselines but do not replace representative external execution.

### 3. Backup/restoration and resilience assurance

Record:

- backup/restore identities;
- stores/components covered;
- execution timestamps;
- measured RPO/RTO observations where applicable;
- integrity validation;
- operator/assessor sign-off;
- unresolved limitations.

### 4. Platform and configuration hardening

Review the actual target platform for:

- network/TLS restrictions;
- container/runtime hardening;
- PostgreSQL/OpenSearch/Redis/object-storage configuration;
- operational access paths;
- logging/monitoring exposure;
- patch/version posture;
- approved deviations and residual risk.

### 5. Secrets-management and IAM acceptance

Evidence must cover:

- approved secret-management mechanism;
- least-privilege application/service identities;
- human/service-account separation;
- credential lifecycle/rotation expectations;
- bearer-token trust architecture;
- absence of local-development credential exceptions in the accepted environment;
- explicit exclusion of secret values from retained repository evidence.

### 6. Operational and stakeholder assurance

Obtain accountable acceptance from the required service/security/privacy/governance stakeholders for the production-candidate operating model.

Technical access and infrastructure ownership remain distinct from intelligence review and external-share approval.

### 7. Deployment and production-candidate assurance

Evidence must tie the accepted staging/production-candidate state to:

- immutable release/image/deployment identity;
- approved change record;
- rollback/recovery target;
- monitoring/on-call/escalation model;
- unresolved finding/risk disposition.

Production acceptance itself remains a Phase 10 decision and cannot be inferred from Phase 9 evidence alone.

## Threat, CVE and vendor-advisory provenance

Assurance evidence dependent on software/platform state must include a time-bounded review of relevant public threat intelligence, CVEs and vendor advisories against the immutable target.

Record:

- source/provenance;
- review time;
- applicability to actual component/version;
- confidence;
- disposition/remediation.

Generic or stale advisory summaries do not satisfy this requirement.

## Evidence rules

- Evidence must be independently observable, attributable and dated.
- Target-bound evidence must identify the immutable target state.
- Missing, stale, inaccessible, inferred or contradictory evidence is not `PASS`.
- Repository CI, Docker Compose and staging emulators cannot substitute for independent execution.
- Findings may not be silently waived; unresolved findings require explicit authorized risk disposition.
- Secret values, credentials, tokens and unnecessary personal data must not be retained in repository evidence.
- Intelligence `reviewed` and external `share approved` remain separate authorities.
- Production acceptance cannot be inferred from staging or assurance success.

## Acceptance rule

Phase 9 may become `PASS` only after all required assurance classes for the agreed scope are complete, reviewable and tied to the accepted target identity, and findings/residual risk have accountable disposition.

Issue #1 remains authoritative for the external production-readiness gate state.

## Current next dependency

**Complete and accept Phase 8 real production-equivalent staging before crediting Phase 9 completion.**
